Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Cancer. 2011 Sep 1;117(17):3908-16. doi: 10.1002/cncr.25995. Epub 2011 Mar 1.
Several trials have been conducted to determine the feasibility of preoperative radiotherapy (RT) for gastric cancer. However, the absolute benefit from radiotherapy remains to be defined. In this study, the authors examined the use of preoperative RT (Pre-RT) and postoperative RT (PORT) in patients with gastric cancer from the Surveillance, Epidemiology, and End Results (SEER) database.
The overall survival of patients who had nonmetastatic, resected gastric cancer between 2000 and 2006 was analyzed from the SEER database. Kaplan-Meier survival curves comparing Pre-RT, PORT, and no RT (No-RT) were analyzed using the log-rank test. A multivariate analysis (MVA) was conducted using Cox proportional hazards regression.
The authors identified 10,251 patients. There was no survival benefit for patients who received Pre-RT or PORT compared with No-RT patients for the entire cohort. Conversely, among lymph node-positive patients, there was a significant survival benefit from both Pre-RT and PORT compared with No-RT (log-rank test: PORT, P < .0001; Pre-RT, P = .0261). The median survival and 5-year overall survival among lymph node-positive patients were 22 months and 24%, respectively, for Pre-RT;29 months and 34%, respectively, for PORT; and 19 months and 20%, respectively, for No-RT. MVA demonstrated that Pre-RT, PORT, and removing ≥ 15 lymph nodes were independent predictors of improved survival, whereas tumor classification, lymph node status, tumor size, and tumor location were independent predictors of death.
The current results supported the use of Pre-RT in select patients with gastric cancer. However, additional trials will be needed to confirm these findings.
多项试验已针对胃癌术前放疗(RT)的可行性进行了研究。然而,放疗的绝对获益仍有待确定。本研究作者利用美国监测、流行病学和最终结果(SEER)数据库,对接受胃癌根治术患者的术前放疗(Pre-RT)和术后放疗(PORT)的应用进行了评估。
从 SEER 数据库中分析了 2000 年至 2006 年期间非转移性、可切除胃癌患者的总生存情况。采用对数秩检验比较 Pre-RT、PORT 和无放疗(No-RT)患者的 Kaplan-Meier 生存曲线。采用 Cox 比例风险回归进行多变量分析(MVA)。
作者确定了 10251 例患者。与 No-RT 患者相比,Pre-RT 或 PORT 患者的总生存无获益。然而,在淋巴结阳性患者中,Pre-RT 和 PORT 与 No-RT 相比均有显著生存获益(log-rank 检验:PORT,P<.0001;Pre-RT,P=.0261)。淋巴结阳性患者的中位生存时间和 5 年总生存率分别为 Pre-RT 组 22 个月和 24%,PORT 组 29 个月和 34%,No-RT 组 19 个月和 20%。MVA 表明,Pre-RT、PORT 和清除≥15 枚淋巴结是生存改善的独立预测因素,而肿瘤分级、淋巴结状态、肿瘤大小和肿瘤位置是死亡的独立预测因素。
目前的结果支持在特定胃癌患者中应用 Pre-RT。然而,需要开展更多的临床试验来证实这些发现。